GINA Guidelines and Biologics for Treatment of Asthma

Author(s):

Nicole Chase, MD, FAAP, FACAAI, FAAAAI,S. Shahzad Mustafa, MD

Sande Okelo, MD, leads a discussion on the updates in the GINA 2021 report regarding difficult-to-treat and severe asthma, as well as considerations for GINA Step 4 and 5 treatment approaches.

EP: 1.External Factors and Seasonality of Asthma

EP: 2.Endotypes and Phenotypes in Asthma

EP: 3.Type 2 Inflammation and Biomarkers in Asthma

EP: 4.Moderate/Severe/Uncontrolled Asthma Classification

EP: 5.Thinking About Endotypes when Managing Asthma

EP: 6.Use of Oral Corticosteroids in Asthma

EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma

EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma

EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

EP: 10.Biologics in Asthma

Now Viewing

GINA Guidelines and Biologics for Treatment of Asthma

EP: 1.External Factors and Seasonality of Asthma

EP: 2.Endotypes and Phenotypes in Asthma

EP: 3.Type 2 Inflammation and Biomarkers in Asthma

EP: 4.Moderate/Severe/Uncontrolled Asthma Classification

EP: 5.Thinking About Endotypes when Managing Asthma

EP: 6.Use of Oral Corticosteroids in Asthma

EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma

EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma

EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

EP: 10.Biologics in Asthma

EP: 11.GINA Guidelines and Biologics for Treatment of Asthma

EP: 12.Use of Biologics for Asthma in Patients with Allergies

EP: 13.Treatment of Asthma in Pediatric Patients

EP: 14.Atopic March in Pediatric Patients

EP: 15.Use of Biologics in Pediatric Patients and Conversations with Parents

EP: 16.Biologic Options in Pediatric Asthma

EP: 17.Advice for Clinicians Managing Asthma